Form 8-K · Current report
Johnson & Johnson 8-K, filed Oct 13, 2026
- Filed
- CIK
- 0000200406
- Accession no.
- 0000200406-26-000189
Summary
Johnson & Johnson reported third-quarter 2026 sales growth of 5.9% to $25.4 billion and raised its full-year 2026 guidance to estimated reported sales of $101.2 billion and adjusted EPS of $11.10, while diluted EPS fell to $0.09 on a one-time special charge tied to a proposed talc litigation resolution and two M&A deals. Chief Executive Joaquin Duato said the quarter's momentum and investments in high-growth areas give the company line of sight to double-digit growth by the end of the decade.
Key points
- Third-quarter 2026 reported sales rose 5.9% to $25.4 billion, with operational growth of 6.0% and adjusted operational growth of 6.1%.
- Diluted EPS was $0.09 versus $2.12 a year earlier, reflecting a one-time special charge for the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration; adjusted EPS was $2.59.
- Full-year 2026 guidance was raised to estimated reported sales of $101.2 billion (7.4% growth at the midpoint) and adjusted EPS of $11.10, up $0.06 from prior guidance.
- Quarterly regulatory and clinical news included FDA market authorization for the OTTAVA robotic surgical system, approval of IMAAVY for warm autoimmune hemolytic anemia, and priority review for RYBREVANT FASPRO in advanced head and neck cancer.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of operations and financial condition On October 13, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 27, 2026. Item 9.01 Financial statements and exhibits (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated October 13, 2026 for the period ended September 27, 2026 99.2 Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal third quarter and nine months 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.